Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 570 JPY -3.72% Market Closed
Market Cap: 8.4B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Perseus Proteomics Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Additional Paid In Capital
ÂĄ2.3B
CAGR 3-Years
36%
CAGR 5-Years
16%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Additional Paid In Capital
ÂĄ6.5B
CAGR 3-Years
2%
CAGR 5-Years
7%
CAGR 10-Years
1%
PeptiDream Inc
TSE:4587
Additional Paid In Capital
ÂĄ4.6B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
5%
Takara Bio Inc
TSE:4974
Additional Paid In Capital
ÂĄ32.9B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Pharma Foods International Co Ltd
TSE:2929
Additional Paid In Capital
ÂĄ1.8B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
C
Cuorips Inc
TSE:4894
Additional Paid In Capital
ÂĄ6.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
8.4B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
732.02 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Additional Paid In Capital?
Additional Paid In Capital
2.3B JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Additional Paid In Capital amounts to 2.3B JPY.

What is Perseus Proteomics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
16%

Over the last year, the Additional Paid In Capital growth was 1%. The average annual Additional Paid In Capital growth rates for Perseus Proteomics Inc have been 36% over the past three years , 16% over the past five years .

Back to Top